1. Home
  2. SWVL vs LEXX Comparison

SWVL vs LEXX Comparison

Compare SWVL & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Swvl Holdings Corp

SWVL

Swvl Holdings Corp

HOLD

Current Price

$1.37

Market Cap

15.6M

ML Signal

HOLD

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$0.72

Market Cap

16.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SWVL
LEXX
Founded
2017
2004
Country
United Arab Emirates
Canada
Employees
284
7
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.6M
16.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SWVL
LEXX
Price
$1.37
$0.72
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.50
AVG Volume (30 Days)
15.6K
149.3K
Earning Date
04-02-2026
04-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$601.47
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.32
$0.46
52 Week High
$4.99
$1.70

Technical Indicators

Market Signals
Indicator
SWVL
LEXX
Relative Strength Index (RSI) 39.55 52.38
Support Level $1.34 $0.65
Resistance Level $3.83 $0.85
Average True Range (ATR) 0.07 0.07
MACD -0.00 0.00
Stochastic Oscillator 22.41 49.31

Price Performance

Historical Comparison
SWVL
LEXX

About SWVL Swvl Holdings Corp

Swvl Holdings Corp is a technology-driven mobility company that aims to provide reliable, safe, cost-effective and environmentally responsible mass transit solutions. It provides mobility solutions for enterprises and government and individual commuters across-multiple markets with clients such as Amazon, Bosch, E&, P&G and Siemens. The Company operates in Egypt, Saudi Arabia and the UAE.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: